A novel therapeutic strategy for mycoplasma infectious diseases

Personalized Medicine Universe Pub Date : 2015-07-01 DOI:10.1016/j.pmu.2015.04.005

Kazuhiro Matsuda

{"title":"A novel therapeutic strategy for mycoplasma infectious diseases","authors":"Kazuhiro Matsuda","doi":"10.1016/j.pmu.2015.04.005","DOIUrl":null,"url":null,"abstract":"<div>Mycoplasma Infectious Diseases (MID) are systemic illnesses that cause vasculitis and neuritis. MID not only includes pneumonia but also diseases such as asthma, arthritis, nephritis, meningitis, encephalitis, dermatitis, pancreatitis, hepatitis, and hematologic illnesses. The broader concept of MID encompasses acute to chronic phases with diverse symptoms. Therefore, it is often confusing and difficult to identify Mycoplasma-infected patients among those with incurable diseases, such as autoimmune diseases, rheumatic diseases, nervous system disorders, and hematological disorders. Regrettably, conventional diagnosis has only been available for pneumonia, although it is critical to identify MID at early stages for effective medical treatment. A cutting-edge technology has made it possible to measure the amount of specific antibodies to species-specific mycoplasma glycolipid-antigens. This new technology provides a reliable marker to follow the state of MID by monitoring antibody titer fluctuations. A novel therapeutic strategy based on new serological diagnostics is introduced in this review.</div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 32-39"},"PeriodicalIF":0.0000,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2015.04.005","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized Medicine Universe","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2186495015000164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 5

Abstract

Mycoplasma Infectious Diseases (MID) are systemic illnesses that cause vasculitis and neuritis. MID not only includes pneumonia but also diseases such as asthma, arthritis, nephritis, meningitis, encephalitis, dermatitis, pancreatitis, hepatitis, and hematologic illnesses. The broader concept of MID encompasses acute to chronic phases with diverse symptoms. Therefore, it is often confusing and difficult to identify Mycoplasma-infected patients among those with incurable diseases, such as autoimmune diseases, rheumatic diseases, nervous system disorders, and hematological disorders. Regrettably, conventional diagnosis has only been available for pneumonia, although it is critical to identify MID at early stages for effective medical treatment. A cutting-edge technology has made it possible to measure the amount of specific antibodies to species-specific mycoplasma glycolipid-antigens. This new technology provides a reliable marker to follow the state of MID by monitoring antibody titer fluctuations. A novel therapeutic strategy based on new serological diagnostics is introduced in this review.

查看原文本刊更多论文

支原体传染病的新治疗策略

支原体传染病(MID)是引起血管炎和神经炎的全身性疾病。MID不仅包括肺炎，还包括哮喘、关节炎、肾炎、脑膜炎、脑炎、皮炎、胰腺炎、肝炎和血液病等疾病。更广泛的MID概念包括具有不同症状的急性到慢性期。因此，在自身免疫性疾病、风湿性疾病、神经系统疾病、血液系统疾病等不治之症患者中，支原体感染患者往往难以识别。遗憾的是，传统诊断仅适用于肺炎，尽管在早期阶段识别MID对于有效的医学治疗至关重要。一项尖端技术已经使测量针对物种特异性支原体糖脂抗原的特异性抗体的数量成为可能。这项新技术通过监测抗体滴度波动，提供了一种可靠的标志物来跟踪MID的状态。本文介绍了一种基于新的血清学诊断方法的新型治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Personalized Medicine Universe

自引率

0.00%

发文量